Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00006400 |
|
Recruitment Status :
Completed
First Posted : October 13, 2000
Results First Posted : August 19, 2020
Last Update Posted : August 19, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Hematologic Diseases Anemia, Sickle Cell | Drug: Hydroxyurea Drug: Placebo | Phase 3 |
BACKGROUND:
In 1995, the Multicenter Study of Hydroxyurea (MSH) demonstrated that hydroxyurea is effective in decreasing the frequency of painful crises, hospitalizations for crises, acute chest syndrome, and blood transfusions by 50%. The recently completed phase II study of hydroxyurea in children (PED HUG) demonstrated that children have a response to hydroxyurea similar to that seen in adults in terms of increasing fetal hemoglobin levels and total hemoglobin, and decreasing complications associated with sickle cell anemia. In addition, this study demonstrated that the drug does not adversely affect growth and development between the ages of 5 and 15. A recently completed pilot study of hydroxyurea given to children between the ages of 6 months and 24 months demonstrated that the drug is tolerated well by small infant, and that the fetal hemoglobin switch can be forced to remain in the "on position" by hydroxyurea administration.
A Special Emphasis Panel (SEP) met on April 12, 1996 to review the results of the MSH trial and the progress to date of the PED HUG study. The SEP recommended that NHLBI undertake the BABY HUG trial.
DESIGN NARRATIVE:
BABY HUG is a randomized, double-blind, placebo-controlled study to determine if hydroxyurea can prevent the onset of chronic end organ damage in young children with sickle cell anemia. Approximately 200 children with sickle cell disease will be recruited to receive either hydroxyurea or placebo. The children will be screened at study entry for signs of abnormal brain, kidney, pulmonary, and splenic function, and developmental milestones. They will then be randomly assigned to receive either hydroxyurea or placebo and followed yearly to assess chronic end organ damage of the major organ systems. The primary endpoint will be a 50% reduction in rates of damage to the major organs with surrogate markers of organ function during follow-up in Phase II of the trial.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 193 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Prevention |
| Official Title: | Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) |
| Study Start Date : | August 2000 |
| Actual Primary Completion Date : | September 2009 |
| Actual Study Completion Date : | September 2009 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Hydroxyurea
Participants will receive hydroxyurea.
|
Drug: Hydroxyurea
Participants will receive hydroxyurea. |
|
Placebo Comparator: Placebo
Participants will receive placebo.
|
Drug: Placebo
Participants will receive placebo. |
- Treatment Differences of the Change in Qualitative Splenic Function From Baseline [ Time Frame: Before initiation of treatment and at 2 years ]
Primary Endpoint: Spleen function was assessed by uptake of 99mTc sulfur colloid on liver-spleen scan before initiation of treatment (baseline) and 2 years later (exit). The results of each of the two scans were categorized as normal, functional but abnormal, or not functional by a panel of nuclear medicine specialists blinded to treatment assignment. The proportion of patients whose paired scans demonstrated a decline in splenic function was compared in the hydroxyurea versus placebo groups.
The change in splenic function from baseline to 2 years was defined as worse if it changed from normal to decreased or absent, or decreased to absent; and not worse if it changed from decreased to decreased, normal to normal, or decreased to normal.
- Change From Baseline in the Renal Function That Was Measured by Diethylenetriaminepentaacetic Acid (DTPA) Glomerular Filtration Rate (GFR) [ Time Frame: Before initiation of treatment and at 2 years ]DTPA GFR was originally a co-primary efficacy outcome for the study. Later in May 29, 2009, this measurement was discontinued because of statistical futility (an extremely small chance that the difference between treatment groups would be statistically significant for this outcome) and the small risk posed by the radiation exposure involved with performing the DTPA GFR test. Subjects who had missing data at baseline or 2 years measurement were excluded from the analysis (29 subjects from the hydroxurea, and 31 subjects from the placebo group excluded).
- Change From Baseline in the Renal Function That Was Measured by Glomerular Filtration Rate (GFR) (Calculated Using Schwartz Formula) [ Time Frame: Before initiation of treatment and at 2 years ]Schwartz formula used to calculate GFR is: 0.55× height (cm)/serum creatinine (mg/dL). Where height is in cm and serum creatinine is in mg/dL. Children with missing baseline or 2 years GFR were excluded from the analysis.
- Change From Baseline in the Renal Function That Was Measured by GFR (Calculated Using New Schwartz Formula) [ Time Frame: Before initiation of treatment and at 2 years ]GFR was calculated using new Schwartz formula: 39.1× [height (cm)/serum creatinine (mg/dL)]0.516 × [1.8/cystatin C]0.294 × [30/blood urea nitrogen]0.169 × [1.099]if male × [height(m)/1.4]0.188. Children with missing baseline or 2 years GFR were excluded from the analysis.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 9 Months to 18 Months (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Majority fetal and sickle (FS or SF) hemoglobin pattern confirmed centrally by electrophoresis (screening may begin at 7 months of age)
Exclusion Criteria:
- Chronic transfusion therapy
- Cancer
- Less than 5th percentile (10th percentile for the pilot study) height, weight, or head circumference for age
- Severe developmental delay (e.g., cerebral palsy or other mental retardation, Grade III/IV intraventricular hemorrhage)
- Stroke with neurological deficit
- Surgical splenectomy
- Participating in other clinical intervention trials
- Probable or known diagnosis of Hemoglobin S-Hereditary Persistence of Fetal Hemoglobin
- Known hemoglobin S-beta plus thalassemia (hemoglobin A present)
- Any condition or chronic illness, which in the opinion of the principal investigator, makes participation unadvised or unsafe
- Inability or unwillingness to complete baseline (pre-enrollment) studies, including blood or urine specimen collection, liver-spleen scan, abdominal sonogram, neurological examination, neuropsychological testing, or transcranial Doppler ultrasound (interpretable study not required, but confirmed velocity greater than 200 cm/sec results in ineligibility)
- Previous or current treatment with hydroxyurea (HU) or another anti-sickling drug
-
The following exclusion criteria are transient; patients can be re-evaluated for eligibility:
- Hemoglobin less than 6.0 gm/dL
- Reticulocyte count less than 80,000/cu mm if hemoglobin is less than 9 gm/dL
- Neutrophil count less than 2,000/cu mm
- Platelet count less than 130,000/cu mm
- Blood transfusion in the 2 months prior to study entry unless HbA is less than 10%
- ALT greater than twice the upper limit of normal
- Ferritin less than 10 ng/ml
- Serum creatinine greater than twice the upper limit of normal for age
- Bayley standardized mental score below 70
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00006400
| United States, Alabama | |
| University of Alabama at Birmingham | |
| Birmingham, Alabama, United States, 35233 | |
| United States, District of Columbia | |
| Children's National Medical Center | |
| Washington, District of Columbia, United States, 20010 | |
| Howard University | |
| Washington, District of Columbia, United States, 20060 | |
| United States, Florida | |
| University of Miami | |
| Miami, Florida, United States, 33136 | |
| United States, Georgia | |
| Emory University School of Medicine | |
| Atlanta, Georgia, United States, 30342 | |
| United States, Maryland | |
| Johns Hopkins University | |
| Baltimore, Maryland, United States, 21287 | |
| United States, Michigan | |
| Children's Hospital of Michigan/Wayne State Univ. | |
| Detroit, Michigan, United States, 48201 | |
| United States, Mississippi | |
| University of Mississippi Medical Center | |
| Jackson, Mississippi, United States, 39216 | |
| United States, New York | |
| SUNY Health Science Center, Brooklyn | |
| Brooklyn, New York, United States, 11203 | |
| United States, North Carolina | |
| Duke University Medical Center | |
| Durham, North Carolina, United States, 27710 | |
| United States, Pennsylvania | |
| Drexel University | |
| Philadelphia, Pennsylvania, United States, 19134 | |
| United States, South Carolina | |
| Medical University of South Carolina | |
| Charleston, South Carolina, United States, 29425 | |
| United States, Tennessee | |
| St. Jude Children's Research Hospital | |
| Memphis, Tennessee, United States, 38105 | |
| United States, Texas | |
| University of Texas SW Medical Center | |
| Dallas, Texas, United States, 75390 | |
| Principal Investigator: | Sherron Jackson, MD | Medical University of South Carolina | |
| Principal Investigator: | James F. Casella, MD | Johns Hopkins University | |
| Principal Investigator: | Lori Luchtman-Jones, MD | Children's National Research Institute | |
| Principal Investigator: | Rathi V. Iyer, MD | University of Mississippi Medical Center | |
| Principal Investigator: | Scott T. Miller, MD | SUNY Health Science Center, Brooklyn | |
| Principal Investigator: | Sohail R. Rana, MD | Howard University | |
| Principal Investigator: | Zora R. Rogers, MD | University of Texas SW Medical Center | |
| Principal Investigator: | Bruce W Thompson, Ph.D. | Clinical Trials and Surveys Corp | |
| Principal Investigator: | Julio Barredo, MD | University of Miami Medical Center | |
| Study Chair: | Winfred C. Wang, MD | St. Jude Children's Research Hospital | |
| Principal Investigator: | Courtney Thornburg, MD | Duke University | |
| Principal Investigator: | Thomas Howard, MD | University of Alabama at Birmingham | |
| Principal Investigator: | Lori Luck, MD | Drexel University | |
| Principal Investigator: | R. Clark Brown, MD, PhD | Emory University | |
| Principal Investigator: | Sharada Sarnaik, MD | Wayne State University |
Documents provided by National Heart, Lung, and Blood Institute (NHLBI):
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | National Heart, Lung, and Blood Institute (NHLBI) |
| ClinicalTrials.gov Identifier: | NCT00006400 |
| Other Study ID Numbers: |
89 N01 HB07150 N01 HB07151 N01 HB07152 N01 HB07153 N01 HB07154 N01 HB07155 N01 HB07156 N01 HB07157 N01 HB07158 N01 HB07159 N01 HB07160 |
| First Posted: | October 13, 2000 Key Record Dates |
| Results First Posted: | August 19, 2020 |
| Last Update Posted: | August 19, 2020 |
| Last Verified: | April 2011 |
|
Blood Diseases Sickle Cell Anemia |
|
Anemia Anemia, Sickle Cell Hematologic Diseases Anemia, Hemolytic, Congenital Anemia, Hemolytic Hemoglobinopathies Genetic Diseases, Inborn |
Hydroxyurea Antineoplastic Agents Antisickling Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Nucleic Acid Synthesis Inhibitors |